MedTrace Logo

Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults

NCT04752644 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2023-07-21

No results posted yet for this study

Summary

A Phase 2a, Randomised, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the Recombinant MVA-BN®-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Participants

Conditions

  • RSV Infection

Interventions

BIOLOGICAL

MVA-mBN294B

MVA-BN-RSV (nominal titre 5 x10\*8 Inf.U per 0.5 mL) as intramuscular injections. Liquid frozen suspension, single dose of 0.5ml.

DRUG

Placebo

TBS (Placebo) as intramuscular injections (0.5ml)

Sponsors & Collaborators

  • Bavarian Nordic

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-22
Primary Completion
2021-06-17
Completion
2021-11-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04752644 on ClinicalTrials.gov